The global Interleukin (IL) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Interleukin (IL) is a group of naturally occurring proteins. They mediate communication between cells and regulate cell growth, differentiation, and motility. The major factor driving the demand for interleukin (IL) inhibitors is the increasing prevalence of cancer across the globe. 

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the increasing prevalence of cancer is driving the demand for interleukin (IL) as it supports immune system cells to grow and divide more quickly, which in turn, is driving the growth of the market.

Some major players in the market include Johnson & Johnson Services, Inc., GlaxoSmithKline, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2020, Janssen announced the approval of TREMFYA (guselkumab) from the US Food and Drug Administration (FDA). It is used for the treatment of adult patients with active psoriatic arthritis (PsA) which selectively inhibits interleukin (IL)-23.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Johnson & Johnson Services, Inc., GlaxoSmithKline, and Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Interleukin (IL) Market Report by Segment

By Type

• IL-17

• IL-23

• IL-1

• IL-5

• IL-6

• Others

By Application 

• Rheumatoid Arthritis

• Asthma

• Inflammatory Bowel Disease

• Cancer 

• Others

Global Interleukin (IL) Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa